NCT05514990View on ClinicalTrials.gov

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

October 7, 2026

Study Completion Date

October 7, 2027

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Bortezomib

Given SC or IV

DRUG

Dexamethasone

Given PO, IV, or IM

BIOLOGICAL

Pelareorep

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (2)

90033

RECRUITING

Los Angeles County-USC Medical Center, Los Angeles

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER